MedTech Dive July 1, 2024
The annual number of medtech acquisitions is on course to slump to its lowest level since 2017, according to Needham.
Dive Brief:
- The annual number of medtech acquisitions is on course to slump to its lowest level since 2017, Needham analysts said Friday.
- At the midpoint of the year, deal volumes are down but values are up. The analysts see the potential for increased activity, citing stabilizing interest rates and low valuations. Still, they identified antitrust concerns as a barrier that could persist until at least the presidential election.
- Needham analysts removed Nevro from their list of the top 25 potential acquisition targets due to its “modest growth rate.” Neuropace, Zimvie, Artivion and Masimo joined the list to replace...
Today's Sponsors
Today's Sponsor